Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607113 · ClinicalTrials.gov registry record · Phase 2
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00607113: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00607113 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00607113, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the effect of Avastin on tumor blood flow as determined by functional computed tomography (CT) in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the effect of RAD001 on tumor blood flow as determined by functional CT in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the effect of adding the second agent (Avastin or RAD001) to the first agent (RAD001 or Avastin) on tumor blood flow as determined by functional CT Secondary Objectives: * To determine the clinical activity (objective response rate and progression free survival duration) of Avastin and RAD001 in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the biochemical response rate of Avastin and RAD001 in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the safety and tolerability of Avastin and RAD001 in patients with low or intermediate grade neuroendocrine carcinoma.
Interventions
- DRUG RAD001
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607113
The ClinicalTrials.gov registry entry for NCT00607113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RAD001 is the first listed.
NCT00607113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607113 about?
NCT00607113 is a clinical study titled "Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma". Primary Objectives: * To determine the effect of Avastin on tumor blood flow as determined by functional computed tomography (CT) in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the effect of RAD001 on tumor blood flow as determined by functional CT in patients w...
What is the current status of trial NCT00607113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00607113?
The interventions under investigation include: RAD001 (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00607113?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.